Longhorn Vaccines to Showcase Advances in Flu and AMR Vaccines
Longhorn Vaccines to Present at IDWeek 2024
Longhorn Vaccines and Diagnostics, a notable player in the realm of public health innovation, plans to present groundbreaking data on two of its pioneering vaccine candidates at IDWeek 2024. This prestigious event will be held in Los Angeles, where professionals gather to share insights and advancements in infectious disease research and treatments.
Focus on Influenza and Antimicrobial Resistance
Longhorn is dedicated to addressing significant health threats imposed by seasonal influenza and antimicrobial resistance (AMR). Their innovative approach includes the development of LHNVD-110, an ambitious single peptide universal influenza vaccine that aims to provide broad protection across various strains. Simultaneously, their LHNVD-303 candidate targets AMR by utilizing a strategic blend of lipoteichoic acid, lipopolysaccharide, and peptidoglycan, designed to combat bacteria that are resistant to conventional antibiotics.
Data Presentation Overview
During IDWeek 2024, Longhorn will unveil valuable insights from two critical abstracts that highlight their progress in vaccine development. These presentations promise to shed light on the efficacy of their innovative solutions in tackling pressing global health challenges.
Key Poster Presentations
The company is set to present the following notable posters at the event:
Poster Title: A Single Composite Peptide Vaccine Comprising Conserved Influenza Epitopes Formulated with ALFQ Adjuvant Induced Broadly Reactive Antibodies to Human, Avian, and Swine Influenza Viruses
Presenter: Clara J. Sei, MPH, Vice President of Vaccine and Antibody Development at Longhorn Vaccines & Diagnostics
Poster Session: Adult Vaccines
Session Date: Thursday, October 17, 2024
Session Time: 12:15 PM – 1:30 PM PST
Session Location: Halls JK, Los Angeles Convention Center
Poster Title: Developing Vaccines and Antibodies Targeting Conserved Peptidoglycan, Lipoteichoic Acid, and Lipopolysaccharide Epitopes to Combat Antimicrobial Resistance
Presenter: Nimisha Rikhi, Research Scientist at Longhorn Vaccines & Diagnostics
Poster Session: Novel Agents
Session Date: Friday, October 18, 2024
Session Time: 12:15 PM – 1:30 PM PST
Session Location: Halls JK, Los Angeles Convention Center
Understanding the Importance of IDWeek
IDWeek is a significant gathering for medical professionals focused on infectious diseases. This annual meeting brings together the Infectious Diseases Society of America, Society for Healthcare Epidemiology of America, and other key organizations to discuss advancements and shared challenges in the healthcare field.
About Longhorn Vaccines and Diagnostics
Longhorn Vaccines and Diagnostics is a dynamic One Health company committed to developing broad coverage vaccines and diagnostic tools aimed at combating global public health issues. The organization, founded in 2006, emphasizes the importance of building solutions that have a profound impact on emerging pandemics affecting both humans and animals.
Their flagship product, PrimeStore® Molecular Transport Medium, is an advanced FDA-cleared device designed to collect and transport samples at ambient temperature. This innovation not only facilitates safer handling of infectious disease samples but also ensures the preservation of RNA and DNA, thus enhancing diagnostic efficiency. By bridging the gap between diagnosis and treatment, Longhorn aims to empower healthcare systems and improve patient outcomes worldwide.
Frequently Asked Questions
What is the purpose of Longhorn's presentation at IDWeek 2024?
Longhorn aims to present their pioneering research on the universal influenza vaccine LHNVD-110 and the antimicrobial resistant sepsis vaccine LHNVD-303.
Where will IDWeek 2024 be held?
IDWeek 2024 will take place in Los Angeles, California, serving as a platform for professionals in infectious disease research to gather.
Why are AMR vaccines important?
AMR vaccines are critical due to the rising threat of antibiotic-resistant infections, which pose significant challenges to public health worldwide.
What distinguishes Longhorn's PrimeStore® MTM?
PrimeStore® MTM is unique as it can deactivate pathogens and stabilize genetic material, making it safer and more effective for molecular testing.
How long has Longhorn been in operation?
Longhorn Vaccines and Diagnostics has been operational since 2006, focusing on innovative solutions for public health challenges.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.
Related Articles
- Edible Garden Stock Hits Rock Bottom: What’s Next for EDBL?
- A Deep Dive into Build-A-Bear Workshop's Insider Trading Trends
- Exploring the Growth of Population Health Management Solutions
- Garrett Motion Expands with Zero-Emission Center in China
- Inhibikase Therapeutics Sees Significant Stock Price Surge
- GMM Stock Hits 52-Week Low of $0.61: An Investor's Outlook
- Exploring the Future of Computer Vision: Market Insights Ahead
- BCG Stock Experiences Significant Downturn Amid Market Volatility
- Understanding Blue Owl Capital's Earnings and Market Dynamics
- Understanding Dollar Influence on Global Currencies: Insights
Recent Articles
- Dolomite Market Set to Surpass $5.7 Billion by 2034 Amid Trends
- Introducing the Advancements in DNA Fragment Purification
- Future of Carbon Capture: Growth Projections and Innovations
- Biosero and BioNex Unite to Revolutionize Lab Automation
- Energy Drinks Market Growth Preview: Over $177 Billion by 2031
- Gain Therapeutics Showcases Innovative Parkinson's Drug at Conference
- Allurion's New Findings Showcase Weight Loss and Muscle Retention
- Upcoming Financial Results Announcement from Acme United
- Nimbus Therapeutics Unveils Results on WRN Inhibitor Research
- Click Holdings Limited Commences IPO with $5.6 Million Offering
- Sonnet BioTherapeutics Forms Key Partnership to Tackle Diabetic Neuropathy
- Compact EZBuck™ Regulator for Enhanced Intel Performance
- Exploring Warren Buffett's Key Investments in Top Companies
- TRIMEDX Expands Leadership Team to Drive Innovation Forward
- Insight Into Learning Technologies Group Plc's Market Position
- Ryde Launches Educational Awards to Support Young Learners
- SIMPPLE Ltd. Expands Footprint with New Contracts in ANZ
- Navitas Semiconductor Expands GaNSafe Offerings for Next-Gen Power
- Hurricane Milton's Impact on Global Insurance Landscape
- Cloud ERP Market Growth Driven by AI and Enhanced Efficiency
- HARMAN’s Ready Vision QVUE Wins 2024 Award for Innovative HUD Tech
- Unveiling the Emerging Giants in AI Investments
- Intelligent Bio Solutions Teams with Spirit Group for Impactful Drug Testing
- ClearSign Technologies Strengthens Position with New Burner Order
- Dragos Public Sector: Securing Government’s OT Cyber Landscape
- Aprea Therapeutics Welcomes Dr. Philippe Pultar as Advisor
- Avenue Therapeutics to Join Virtual Summit for Healthcare Insights
- iCoreConnect Partners with Dental Society for Enhanced Solutions
- Bayer Advances Elinzanetant for Menopause Symptom Relief
- Banzai Unveils Plans to Boost Annual Income Potential by $13.5M
- NGE Secures $110 Million Financing for Central Railway Project
- Avenue Therapeutics Showcases Insights at Healthcare Summit
- Recognizing Innovation: NTT's APN Project Wins Prestigious Award
- Empowering Volunteers: Kind Souls Foundation's Innovative Training
- Banzai's Innovative Business Adjustments Aim for Growth and Savings
- MilliporeSigma Unveils Major Investment in Testing Facility
- Helen Of Troy Shares Rise After Strong Q2 Performance Summary
- Entourage Health Updates on Financial Position and Strategy
- Naveris Expands NavDx Test Coverage to Revolutionize Diagnostics
- How XR Technologies are Transforming Manufacturing Operations
- Chartwell Retirement Residences Reveals Upcoming Q3 Results
- Understanding the Disclosure Requirements for Balanced Commercial Property Trust
- Phoenix Capital Group Inspires Young Oil and Gas Talent
- NewsXPartners Corporation Honored with Prestigious Leadership Award
- Target Stocks Shine as Cramer Highlights Buying Opportunities
- Recent Share Transactions by Executive Management at Admiral Group
- Celebrating Innovation: The Inaugural Cobalt Awards by Jack Henry
- Informatica Announces Upcoming Q3 2024 Financial Results Call
- Boeing Faces Challenges Ahead as Strikes and Downgrade Approach
- Understanding Keywords Studios Plc Position Disclosure Insights